Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Partisan Management Group Inc.

This article was originally published in Start Up

Executive Summary

The strategy of Partisan Management Group Inc. is simple; reliance on a small circle of talented, experienced friends to build fledgling medical device companies. Led by Norman Weldon, PhD, and Karen Cassidy, it works. Partisan, an early-stage venture capital investment group which focuses strictly on seed funding for medical device start-ups, has produced a series of solid gains for its investors, twice scoring what anyone in the industry would consider to be home runs.

You may also be interested in...



Awaiting The Part D Shakeout

The Medicare drug benefit has more plans and fewer enrollees than expected. That is a recipe for consolidation, but will the federal government wait for the market to evolve?

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel